Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.41 |
| ▸ | EIF4E | P06730 | 4/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.34 |
| ▸ | PPARD | Q03181 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 4/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PTGIR | P43119 | 3/20 | 0.32 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7527899 | 0.90 | PTGIR (0.40) | PTGDR2MEN1POLBKMT2APTGIR | |
| SCHEMBL7521203 | 0.89 | PTGIR (0.40) | PTGDR2ALDH1A1MEN1POLBKMT2A | |
| SCHEMBL7528905 | 0.89 | PTGDR2 (0.39) | PTGDR2PPARDMEN1POLBKMT2A | |
| SCHEMBL7518701 | 0.87 | PTGDR2 (0.41) | PTGDR2ALDH1A1MEN1POLBKMT2A | |
| SCHEMBL7962801 | 0.86 | PPARA (0.35) | EIF4ECYP19A1PPARDMAPTMEN1 | |
| SCHEMBL7521160 | 0.85 | PTGDR2 (0.43) | PTGDR2EIF4EPPARDMAPTGAA | |
| SCHEMBL7523785 | 0.84 | PTGIR (0.42) | PTGDR2PPARDMEN1POLBKMT2A | |
| SCHEMBL7561844 | 0.84 | PTGIR (0.42) | PTGDR2PPARDMEN1POLBKMT2A | |
| SCHEMBL7518862 | 0.84 | PTGIR (0.42) | PTGDR2PPARDMEN1POLBKMT2A | |
| SCHEMBL7523291 | 0.84 | MAPT (0.35) | PTGDR2EIF4EMAPTALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6417213-B2 | ANTICOAGULANTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-07-09 | — | — | US | disclosed |
| US-20020006944-A1 | Tricyclic compounds, their production and use | OHKAWA SHIGENORI (JP) | 2002-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020006944-A1 | Tricyclic compounds, their production and use | CNR1, PTGER1, PTGDR | PTGDR2 10/4885EIF4E 4472/4885CYP19A1 488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.